Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

Vibeke Strand, Roger A. Levy, Ricard Cervera, Michelle Petri, Helen Birch, William W. Freimuth, Z. John Zhong, Ann E. Clarke

Research output: Contribution to journalArticle

Abstract

Objective: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. Methods: Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multicentre, randomised controlled trials of 52 (BLISS-52; N=865) and 76 (BLISS-76; N=819) weeks' duration. Responders were evaluated by SLE Responder Index at week 52. Patient-reported outcome assessments included SF-36, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and EQ-5D. Results: Mean SF-36 Physical Component Summary (PCS) scores at week 24 was a major secondary endpoint. Baseline SF-36 scores were 1.5 SDs below age-/sex-matched US norms with similar improvement at week 24 across treatment groups. Mean changes from baseline in PCS scores were significantly (p

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number5
DOIs
StatePublished - 2014

Fingerprint

B-Cell Activating Factor
Systemic Lupus Erythematosus
Autoantibodies
Randomized Controlled Trials
Functional assessment
Quality of Life
Health
Fatigue of materials
Patient Outcome Assessment
Therapeutics
Fatigue
Chronic Disease
Placebos
belimumab

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. / Strand, Vibeke; Levy, Roger A.; Cervera, Ricard; Petri, Michelle; Birch, Helen; Freimuth, William W.; Zhong, Z. John; Clarke, Ann E.

In: Annals of the Rheumatic Diseases, Vol. 73, No. 5, 2014, p. 838-844.

Research output: Contribution to journalArticle

@article{b145cf6e840f45c8a97ebe22c2346b69,
title = "Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials",
abstract = "Objective: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. Methods: Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multicentre, randomised controlled trials of 52 (BLISS-52; N=865) and 76 (BLISS-76; N=819) weeks' duration. Responders were evaluated by SLE Responder Index at week 52. Patient-reported outcome assessments included SF-36, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and EQ-5D. Results: Mean SF-36 Physical Component Summary (PCS) scores at week 24 was a major secondary endpoint. Baseline SF-36 scores were 1.5 SDs below age-/sex-matched US norms with similar improvement at week 24 across treatment groups. Mean changes from baseline in PCS scores were significantly (p",
author = "Vibeke Strand and Levy, {Roger A.} and Ricard Cervera and Michelle Petri and Helen Birch and Freimuth, {William W.} and Zhong, {Z. John} and Clarke, {Ann E.}",
year = "2014",
doi = "10.1136/annrheumdis-2012-202865",
language = "English (US)",
volume = "73",
pages = "838--844",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

AU - Strand, Vibeke

AU - Levy, Roger A.

AU - Cervera, Ricard

AU - Petri, Michelle

AU - Birch, Helen

AU - Freimuth, William W.

AU - Zhong, Z. John

AU - Clarke, Ann E.

PY - 2014

Y1 - 2014

N2 - Objective: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. Methods: Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multicentre, randomised controlled trials of 52 (BLISS-52; N=865) and 76 (BLISS-76; N=819) weeks' duration. Responders were evaluated by SLE Responder Index at week 52. Patient-reported outcome assessments included SF-36, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and EQ-5D. Results: Mean SF-36 Physical Component Summary (PCS) scores at week 24 was a major secondary endpoint. Baseline SF-36 scores were 1.5 SDs below age-/sex-matched US norms with similar improvement at week 24 across treatment groups. Mean changes from baseline in PCS scores were significantly (p

AB - Objective: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. Methods: Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multicentre, randomised controlled trials of 52 (BLISS-52; N=865) and 76 (BLISS-76; N=819) weeks' duration. Responders were evaluated by SLE Responder Index at week 52. Patient-reported outcome assessments included SF-36, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and EQ-5D. Results: Mean SF-36 Physical Component Summary (PCS) scores at week 24 was a major secondary endpoint. Baseline SF-36 scores were 1.5 SDs below age-/sex-matched US norms with similar improvement at week 24 across treatment groups. Mean changes from baseline in PCS scores were significantly (p

UR - http://www.scopus.com/inward/record.url?scp=84897990442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897990442&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2012-202865

DO - 10.1136/annrheumdis-2012-202865

M3 - Article

C2 - 23524886

AN - SCOPUS:84897990442

VL - 73

SP - 838

EP - 844

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -